- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04638803
Microdose Pharmacokinetic Study of PRX-P4-003 In Healthy Volunteers
November 9, 2021 updated by: Praxis Bioresearch, LLC
A Phase 0, Open-Label, Crossover Microdose Pharmacokinetic Study of PRX-P4-003 In Healthy Volunteers
The goal of the present study is to confirm in humans the in-vivo bioconversion of a Prodrug (PRX-P4-003) to (-)-fencamfamine (FCF) the active moiety when orally administered as a single microdose.
A second component of the study will evaluate effect of food on pharmacokinetics of PRX-P4-003.
Study Overview
Detailed Description
A crossover study comparing blood concentrations after oral administration of microdoses of (-)-fencamfamine (FCF; 40 µg) or its prodrug form (PRX-P4-003; 100 µg)) in the fasted state will be carried out in 4 healthy male volunteers (Study A).
This will be followed by determination of blood concentrations of (-)-fencamfamine in a separate cohort of 4 volunteers following oral administration of a microdose of PRX-P4-003 (100 µg) in a fed state (Study B).
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96817
- Hawaii Pacific Neuroscience
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Male aged 18 to 45 years. Willing to fast for at least 8 hours overnight and 4 hours after study drug dose (Study A).
- BMI within 18 - 32 kg/m2, inclusive.
- Willing/able to provide signed Informed Consent Form & HIPAA authorization for this study.
- Agreement to use a highly effective method of birth control with partners of childbearing potential during the study and for 1 month after study dosing such as, abstinence, barrier methods.
- Normal heart rate (50 to 100 bpm) and blood pressure (diastolic 60-85 mm Hg and systolic 90 to 130 mm Hg, inclusive) at Screening and Day 0.
- Nonsmoker or has not smoked within the past 6 months of Screening Visit 1 and throughout study participation. Use of recreational and/or medicinal marijuana are NOT permitted within 3 months prior to Screening and during the study. Marijuana use should not be initiated after Screening.
- Able to communicate well with the Investigator and to comply with the study procedures, requirements, restrictions, and directions of the clinic staff.
Exclusion Criteria:
Main Criteria for Exclusion:
Subjects who meet the following criteria are excluded from study participation
- History or presence of clinically significant respiratory, GI, renal, hepatic, hematological, neurological (including history of seizure), cardiovascular, psychiatric (including known addictive disorders), musculoskeletal, genitourinary, immunological, or dermatological disorders. The existence of any surgical or medical condition that, in the judgment of the clinical Investigator, might jeopardize the subject's safety, tolerability or interfere with the absorption, distribution, metabolism or excretion of the study drug.
- Any history of suicide attempts or current suicidal ideation.
- Abnormal clinically significant laboratory, physical, or neurological findings during screening.
- Abnormal and clinically significant ECG (as determined by the Investigator or his/her designee) at Screening or Day -0. Abnormalities include, but are not limited to, QTc interval (average of three ECGs) greater than or equal to 450 msec based on 12 lead ECG at Screening or Day -1. Subjects with a history of congenitally prolonged QT interval.
- In the 14 days (or 5 half-lives, whichever is longer) prior to dosing, the need for prescription medications.
- Use of acetaminophen greater than a single dose of 1000 mg up to 3 days prior to Day 1.
- Use of any investigational drug or medical device within 3 months prior to study admission.
- Known hypersensitivity to, or intolerance of, drugs with the same mechanism of action as PRX-P4-003 or (-)-fencamfamine.
- Donation or loss of greater than 500 mL of blood in the 8 weeks before dosing. or planned donation of blood at any time during trial participation.
- History of alcohol abuse (defined as regular or daily consumption of more than 4 alcoholic drinks per day) or drug addiction within the past 2 years, as determined by the Investigator. A positive urine drug, or positive alcohol urine (or breath) test at Screening or Day-1.
- Unwillingness to refrain from alcohol, or illicit or recreational drugs, within 24 hours prior to Day -1and during inpatient period.
- Seropositive for Hepatitis B, Hepatitis C, (tested during screening) or known HIV infection.
- The subject is unwilling or unable to comply with the protocol or scheduled appointments.
- The subject is unable to understand verbal or written English or any other language for which a certified translation of the approved informed consent is available.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NON_RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Crossover (fasted)
On Day 1 subjects are dosed with 100 µg of PRX-P4-003 and PK samples are drawn according to protocol, on Day 15 subjects are dosed with 40 µg of (-)-FCF.
Both treatment will be administered under the fasted conditions.
|
sequential study
Other Names:
|
EXPERIMENTAL: Single Group (fed)
On Day 1 subjects are dosed with 100 µg of PRX-P4-003 and PK samples are drawn according to protocol.
The treatment will be administered under the fed condition.
|
sequential study
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Outcome
Time Frame: 24 hours
|
Plasma (-)-FCF exposure (AUC 0-t) after Oral dosing of PRX-P4-003 and (-)-FCF
|
24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Kore Liow, MD, Hawaii Pacific Neuroscience
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
February 25, 2021
Primary Completion (ACTUAL)
October 30, 2021
Study Completion (ACTUAL)
October 31, 2021
Study Registration Dates
First Submitted
November 4, 2020
First Submitted That Met QC Criteria
November 16, 2020
First Posted (ACTUAL)
November 20, 2020
Study Record Updates
Last Update Posted (ACTUAL)
November 10, 2021
Last Update Submitted That Met QC Criteria
November 9, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PBR001
- R44116764 (OTHER_GRANT: NIMH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States